MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.amjms.2026.07.001

Медицинская библиотека · The American journal of the medical sciences · 2026

Effects of CTLA4-Ig, rituximab, and rapamycin on rat-to-mouse cardiac xenograft survival.

Chen Rao, Ren Yifan, Ma Xinyi, Jin Wenqiang, Xie Baiyi, Li Xiaofei, Ma Yunhan

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Xenotransplantation addresses the critical shortage of human organs and tissues; however, innate immune responses and acute humoral rejection (AHR) limit xenograft survival, the regimen of combined medication remains to be further explored.

METHODS

This study aimed to determine whether a clinically applicable immunosuppressive regimen consisting of CTLA4-Ig, rituximab, and rapamycin could synergistically prolong xenograft survival. Hearts were harvested from Sprague-Dawley (SD) rats and transplanted into C57BL/6 mice. Recipient animals were randomly divided into three groups: an untreated control group, a CTLA4-Ig monotherapy group, or a combination therapy group receiving the triple immunosuppressive regimen.

RESULTS

In the control group, cardiac xenografts were rejected within 10 days, characterized by cell-mediated rejection and AHR. In contrast, the combination therapy significantly prolonged xenograft survival and suppressed immune rejection in the treated recipients. Notably, infiltration of T cells, B cells, dendritic cells, macrophages, and natural killer (NK) cells was markedly reduced, complement deposition was decreased, and the production of xeno-reactive antibodies and proinflammatory cytokines were lowered. Furthermore, we confirmed that the combination therapy confers enhanced protection against xenograft injury via inhibition of the PI3K/mTOR signaling pathway.

CONCLUSIONS

These findings strongly support the rationale for administering CTLA4-Ig, rituximab, and rapamycin to constrain innate immune responses and alleviate AHR in xenotransplantation.

Для цитирования: Chen Rao, Ren Yifan, Ma Xinyi, Jin Wenqiang, Xie Baiyi, Li Xiaofei, Ma Yunhan. Effects of CTLA4-Ig, rituximab, and rapamycin on rat-to-mouse cardiac xenograft survival.. The American journal of the medical sciences. 2026. DOI: 10.1016/j.amjms.2026.07.001.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.